Conference Coverage
Sofosbuvir-ribavirin treats hepatitis C virus genotypes 2, 3
Major finding: Sustained virologic response occurred in 93% after 12 weeks of treatment for genotype 2 and in 85% after 24 weeks of therapy for...
CHICAGO – The oral drug duo of sofosbuvir and ribavirin produced good cure rates in a study of 419 patients with hepatitis C genotype 2 or 3.
Dr. Bruce R. Bacon, who was not involved in the study, highlighted the regimen’s efficacy even in patients with cirrhosis or who had failed previous therapy. Hear his perspective on treating genotypes 2 and 3 in this interview at the annual Digestive Disease Week.
Dr. Bacon is the James F. King Endowed Chair in Gastroenterology and a professor of medicine at Saint Louis University.
He reported financial associations with Gilead Sciences, which funded the study, and with AbbVie and Janssen Pharmaceuticals.
On Twitter @sherryboschert
